|

ITI-1284 20 mg Clinical Trials

2 actively recruiting trials across 2 locations

No change since August 2026

Pipeline

Phase 2: 2

Top Sponsors

  • Intra-Cellular Therapies, Inc.2

Indications

  • Generalized Anxiety Disorder2
  • Anxiety2

Birmingham, Alabama1 trial

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder

University of Alabama at Birmingham

Phase 2

Glendale, California1 trial

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Behavioral Research Specialists LLC

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.